Médecine

Paramédical

Autres domaines


S'abonner

The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study - 13/03/20

Doi : 10.1016/j.jaad.2019.10.065 
Norbertus A. Ipenburg, MD a, Serigne N. Lo, PhD a, Ricardo E. Vilain, MBBS, PhD a, Lodewijka H.J. Holtkamp, MD a, b, James S. Wilmott, PhD a, c, Omgo E. Nieweg, MD, PhD a, c, d, John F. Thompson, MD a, c, d, Richard A. Scolyer, MD a, c, e,
a Melanoma Institute Australia, Sydney, New South Wales, Australia 
b Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands 
c Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia 
d Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia 
e Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia 

Reprint requests: Richard A. Scolyer, MD, Melanoma Institute Australia, 40 Rocklands Road, North Sydney, NSW 2065, Australia.Melanoma Institute Australia40 Rocklands RoadNorth SydneyNSW2065Australia

Abstract

Background

Mitotic rate is a strong predictor of outcome in adult patients with primary cutaneous melanoma, but for children and adolescent patients this is unknown.

Objective

We sought to assess the prognostic value of primary tumor mitotic rate in children and adolescents with primary melanoma.

Methods

This was a cohort study of 156 patients who were <20 years of age and who had clinically localized cutaneous melanoma. Patients <12 years of age were classified as children and those 12 to 19 years of age as adolescents. Clinicopathologic and outcome data were collected. Recurrence-free and melanoma-specific survival were calculated. Univariable and multivariable analyses were performed using Cox proportional hazard models.

Results

Thirteen of 156 patients (8%) were children. The mitotic rate was ≥1/mm2 in 104 patients (67%) and correlated with increasing Breslow thickness. A positive sentinel node was found in 23 of 61 patients (38%) in whom a sentinel lymph node biopsy specimen was obtained. The median follow-up was 61 months. Five-year melanoma-specific and recurrence-free survival rates were 91% and 84%, respectively. Mitotic rate was a stronger predictor of outcome than tumor thickness and was the only factor independently associated with recurrence-free survival.

Limitations

This research was conducted at a single institution and the sample size was small.

Conclusion

Mitotic rate is an independent predictor of recurrence-free survival in children and adolescents with clinically localized melanoma.

Le texte complet de cet article est disponible en PDF.

Key words : adolescent, children, dermatopathology, melanoma, mitosis, mitotic rate, oncology, pathology, pediatric, prognosis, recurrence

Abbreviations used : CI, HR, MIA, MSS, RFS, SN, SNB


Plan


 Funding sources: None.
 Dr Ipenburg had travel, accommodation, and meeting expenses paid by Janssen-Cilag and Novartis. Dr Thompson received honoraria for advisory board membership from GlaxoSmithKline, Merck Sharp Dohme, Bristol Myers Squibb, and Provectus. Dr Scolyer received professional services fees from Merck Sharp Dohme, Novartis, Myriad, and NeraCare. Drs Nieweg, Holtkamp, Lo, Vilain, and Wilmott have no conflicts of interest to disclose.
 This study was approved by the Melanoma Institute Australia Research Committee and the Sydney Local Health District Ethics Review Committee (Protocol No. X15-0454 and HREC/11/RPAH/444).


© 2019  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 82 - N° 4

P. 910-919 - avril 2020 Retour au numéro
Article précédent Article précédent
  • Predictors of hospital readmission in United States adults with psoriasis
  • Brian T. Cheng, Jonathan I. Silverberg
| Article suivant Article suivant
  • Detection of subclinical disease with baseline and surveillance imaging in high-risk cutaneous squamous cell carcinomas
  • Jacqueline M. Maher, Chrysalyne D. Schmults, Fadi Murad, Pritesh S. Karia, Carol B. Benson, Emily Stamell Ruiz

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.